To improve respiratory-gated radiotherapy accuracy, we developed a machine learning approach for markerless tumor tracking and evaluated it using lung cancer patient data. Digitally reconstructed radiography (DRR) datasets were generated using planning 4DCT data. Tumor positions were selected on respective DRR images to place the GTV center of gravity in the center of each DRR. DRR subimages around the tumor regions were cropped so that the subimage size was defined by tumor size. Training data were then classified into two groups: positive (including tumor) and negative (not including tumor) samples. Machine learning parameters were optimized by the extremely randomized tree method. For the tracking stage, a machine learning algorithm was generated to provide a tumor likelihood map using fluoroscopic images. Prior probability tumor positions were also calculated using the previous two frames. Tumor position was then estimated by calculating maximum probability on the tumor likelihood map and prior probability tumor positions. We acquired treatment planning 4DCT images in eight patients. Digital fluoroscopic imaging systems on either side of the vertical irradiation port allowed fluoroscopic image acquisition during treatment delivery. Each fluoroscopic dataset was acquired at 15 frames per second. We evaluated the tracking accuracy and computation times. Tracking positional accuracy averaged over all patients was 1.03 ± 0.34 mm (mean ± standard deviation, Euclidean distance) and 1.76 ± 0.71 mm ([Formula: see text] percentile). Computation time was 28.66 ± 1.89 ms/frame averaged over all frames. Our markerless algorithm successfully estimated tumor position in real time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/ab79c5 | DOI Listing |
Blood Adv
January 2025
Mayo Clinic, Rochester, Minnesota, United States.
In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background: Primary intracranial germ cell tumors (iGCTs) are highly malignant brain tumors that predominantly occur in children and adolescents, with an incidence rate ranking third among primary brain tumors in East Asia (8%-15%). Due to their insidious onset and impact on critical functional areas of the brain, these tumors often result in irreversible abnormalities in growth and development, as well as cognitive and motor impairments in affected children. Therefore, early diagnosis through advanced screening techniques is vital for improving patient outcomes and quality of life.
View Article and Find Full Text PDFJCO Glob Oncol
January 2025
Uganda Cancer Institute, Department of Radiotherapy, Kampala, Uganda.
The evolution of radiation therapy in Uganda has been a journey marked by significant milestones and persistent challenges. Since the inception of radiotherapy services in 1988-1989, there has been a concerted effort to enhance cancer treatment services. The early years were characterized by foundational developments, such as the installation of the first teletherapy units, low-dose-rate brachytherapy units, and conventional simulators, and the recognition of radiation oncologists and medical physicist professionals laid the groundwork for radiotherapy treatment modalities.
View Article and Find Full Text PDFJCO Glob Oncol
January 2025
Department of Public Health, Myungsung Medical College, Addis Ababa, Ethiopia.
Purpose: To analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia.
Materials And Methods: We conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016, to December 31, 2022. Data were extracted from patients' medical records, and vital status was ascertained from the patients' charts or by phone call to the next of kin.
JCO Glob Oncol
January 2025
Cancer Control and Research Division, Philippine Cancer Center, Manila, Philippines.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!